BrainsWay (BWAY) Q2 2024: 28% Revenue Growth Propels Deep TMS Install Base Past 1,200
BrainsWay’s Q2 showcased robust demand for its deep TMS platform, with accelerated system placements and expanding clinical indications driving both revenue and profitability momentum. The company’s balance sheet strength and focused reinvestment strategy set the stage for continued international expansion and deeper U.S. penetration, particularly among elderly and institutional segments. Raised guidance and regulatory wins reinforce a durable growth trajectory into the back half of 2024.
Summary
- Clinical Indication Expansion: FDA label extension unlocks new elderly patient markets for deep TMS.
- International Channel Activation: Multi-year Canada distribution deal and Asia-Pacific momentum diversify revenue streams.
- Profitability Durability: Sustained margin leverage and positive cash flow enable strategic reinvestment.
Business Overview
BrainsWay develops, manufactures, and commercializes deep transcranial magnetic stimulation (deep TMS) systems, non-invasive medical devices used for treating neuropsychiatric disorders such as major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The company generates revenue through system sales, leases, and pay-per-use models across clinics, hospitals, and mental health networks. Its business is split between the U.S. (about 80% of installed base) and international markets, with a growing presence in Asia, Europe, and now Canada.
Performance Analysis
BrainsWay delivered a 28% year-over-year revenue increase in Q2 2024, driven by robust demand for its deep TMS systems and successful expansion into new geographies. System placements reached 114 in the first half, a 13% increase over the prior year period, bringing the total install base to 1,215. Gross margins improved to 75%, reflecting favorable mix and operational leverage, while operating expenses remained disciplined, enabling a swing to operating profit and net income for the quarter.
The company’s positive adjusted EBITDA for a fourth consecutive quarter and rising cash balance ($48.1 million, no debt) underscore its ability to self-fund growth. Sales and marketing spend was slightly lower year-over-year, while R&D investment remained steady as BrainsWay advanced clinical protocols and broadened indications. The company’s raised revenue guidance (now $38.5–$40 million for 2024) signals confidence in both U.S. enterprise pipeline and international channel activation.
- Install Base Scale: System placements accelerated, with Q2 outpacing Q1, supporting recurring revenue and market penetration.
- OCD Indication Uptake: OCD treatment capability remains active on half the install base, supporting utilization growth and reimbursement tailwinds.
- Cash Flow Inflection: Positive operating and free cash flow provide flexibility for reinvestment and potential capital return options.
BrainsWay’s performance reflects a business model leveraging both hardware placements and recurring usage, with expanding clinical utility and international reach supporting durable growth.
Executive Commentary
"Our outlook for the second half of 2024 remains strong and we are now raising the lower end of the guidance for full year 2024 revenue to a range of $38.5 million to $40 million. Therefore, we are now projecting growth of between 21% and 25% over our 2023 revenues."
Hadar Levy, Chief Executive Officer
"As you can see, we grow over a quarter by $1 million with the revenue, which most of it goes directly to our net profit. And our plan is to continue with our profitability through the second half of the year."
Ido Marom, Chief Financial Officer
Strategic Positioning
1. Indication and Regulatory Expansion
BrainsWay’s FDA label extension for MDD patients up to age 86 significantly expands its addressable market, especially among elderly populations and institutional settings such as nursing homes. This regulatory milestone positions deep TMS as the only TMS modality cleared for this demographic, providing a unique competitive edge and new reimbursement opportunities.
2. International Channel Development
The company’s exclusive, multi-year Canadian distribution agreement marks a major channel activation outside the U.S., with minimum order commitments and a large salesforce footprint. Ongoing traction in Asia-Pacific (notably India, South Korea, Taiwan, Thailand) and Europe (France, Italy, Spain) further diversifies revenue and reduces dependence on the U.S. market.
3. Enterprise and Institutional Penetration
BrainsWay is prioritizing partnerships with large enterprise and institutional mental health groups, leveraging its unique lease and pay-per-use business model to drive adoption and recurring revenue. This focus aligns with industry consolidation trends and supports scalable growth across a fragmented provider landscape.
4. Pipeline and Protocol Innovation
The company is piloting its TMS360 system and advancing an accelerated depression treatment protocol, aiming to reduce treatment duration from 30 days to just 6 days via multiple daily sessions. These innovations are designed to boost patient convenience, clinic throughput, and overall market appeal.
5. Capital Allocation Flexibility
With a strong cash position and sustained profitability, BrainsWay is evaluating reinvestment, partnerships, and potential capital returns (such as dividends or buybacks), though management currently favors organic and channel-driven growth initiatives.
Key Considerations
This quarter’s results highlight BrainsWay’s transition from single-product focus to a multi-pronged growth engine with operational leverage and international reach. Investors should weigh the following:
- Elderly Segment Opportunity: FDA label expansion could unlock substantial new demand from nursing homes and geriatric clinics, but requires targeted go-to-market execution.
- International Ramp: Execution risk remains as new distribution partners in Canada and Asia-Pacific must deliver on minimum order commitments and market activation.
- Pipeline Commercialization: Success of the TMS360 pilot and accelerated treatment protocol could materially change system utilization rates and competitive positioning.
- Capital Deployment: Management’s willingness to reinvest and explore partnerships signals a bias toward growth, but investors should monitor for disciplined capital allocation as cash balances rise.
Risks
BrainsWay faces execution risk in scaling international distribution and capturing the expanded elderly segment, as both require new sales motions and clinical education. The company’s revenue concentration in the U.S. (80% of installed base) remains a vulnerability if domestic reimbursement or competitive dynamics shift. Regulatory, supply chain, and macroeconomic headwinds could also impact system placements or utilization rates, particularly in new markets where distributor performance is unproven.
Forward Outlook
For Q3 and Q4 2024, BrainsWay guided to:
- Continued system placement momentum supported by a strong U.S. and international pipeline
- Sustained profitability and positive cash flow, with margin leverage intact
For full-year 2024, management raised guidance:
- Revenue range of $38.5 million to $40 million (21%–25% YoY growth)
Management cited several factors driving confidence:
- Robust backlog and pipeline visibility into the second half
- Anticipated acceleration as new clinical indications and geographies come online
Takeaways
BrainsWay’s Q2 2024 results affirm the company’s ability to scale profitably while unlocking new markets and indications.
- Regulatory Expansion: The FDA age label win provides a durable competitive moat and new revenue streams in the underpenetrated elderly segment.
- International Activation: Multi-year distribution agreements in Canada and Asia-Pacific are set to drive incremental growth, though execution and partner performance will be key watchpoints.
- Pipeline Leverage: Success in accelerated protocols and new system pilots could materially boost utilization and reinforce BrainsWay’s clinical leadership.
Conclusion
BrainsWay is executing on a multi-dimensional growth strategy, combining clinical innovation, geographic expansion, and disciplined operations to deliver both top-line growth and profitability. The company’s raised guidance and strong balance sheet position it well to capitalize on emerging opportunities across mental health treatment markets.
Industry Read-Through
The expansion of FDA-cleared indications for deep TMS in elderly patients sets a precedent for device-based neuropsychiatric therapies, signaling that regulatory and clinical innovation can unlock new demographic segments for mental health solutions. BrainsWay’s channel-driven international strategy and focus on enterprise partnerships reflect broader trends in medtech commercialization, where distribution leverage and recurring revenue models are increasingly critical. Competitors in neuromodulation, digital health, and psychiatric device sectors will need to respond to the rapid pace of clinical protocol innovation and the growing importance of institutional buyers. Investors should watch for similar label expansions and partnership-driven go-to-market models across the mental health technology landscape.